Logo image of AIMD

AINOS INC (AIMD) Stock Fundamental Analysis

NASDAQ:AIMD - Nasdaq - US00902F3038 - Common Stock - Currency: USD

0.4844  -0.04 (-8.43%)

After market: 0.488 +0 (+0.74%)

Fundamental Rating

1

Overall AIMD gets a fundamental rating of 1 out of 10. We evaluated AIMD against 561 industry peers in the Biotechnology industry. AIMD has a bad profitability rating. Also its financial health evaluation is rather negative. AIMD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AIMD has reported negative net income.
AIMD had a negative operating cash flow in the past year.
AIMD had negative earnings in each of the past 5 years.
In the past 5 years AIMD always reported negative operating cash flow.
AIMD Yearly Net Income VS EBIT VS OCF VS FCFAIMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

The Return On Assets of AIMD (-51.57%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -95.79%, AIMD is in line with its industry, outperforming 46.35% of the companies in the same industry.
Industry RankSector Rank
ROA -51.57%
ROE -95.79%
ROIC N/A
ROA(3y)-44.19%
ROA(5y)-139.96%
ROE(3y)-64.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AIMD Yearly ROA, ROE, ROICAIMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K 2K

1.3 Margins

AIMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AIMD Yearly Profit, Operating, Gross MarginsAIMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

1

2. Health

2.1 Basic Checks

AIMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AIMD has been increased compared to 1 year ago.
Compared to 5 years ago, AIMD has more shares outstanding
AIMD has a worse debt/assets ratio than last year.
AIMD Yearly Shares OutstandingAIMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
AIMD Yearly Total Debt VS Total AssetsAIMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

AIMD has an Altman-Z score of -3.76. This is a bad value and indicates that AIMD is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of AIMD (-3.76) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.58 indicates that AIMD is somewhat dependend on debt financing.
The Debt to Equity ratio of AIMD (0.58) is worse than 75.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF N/A
Altman-Z -3.76
ROIC/WACCN/A
WACC7.12%
AIMD Yearly LT Debt VS Equity VS FCFAIMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

A Current Ratio of 1.10 indicates that AIMD should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.10, AIMD is doing worse than 88.24% of the companies in the same industry.
AIMD has a Quick Ratio of 1.06. This is a normal value and indicates that AIMD is financially healthy and should not expect problems in meeting its short term obligations.
AIMD has a worse Quick ratio (1.06) than 86.99% of its industry peers.
Industry RankSector Rank
Current Ratio 1.1
Quick Ratio 1.06
AIMD Yearly Current Assets VS Current LiabilitesAIMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.30% over the past year.
The Revenue for AIMD has decreased by -82.74% in the past year. This is quite bad
The Revenue has been growing by 15.66% on average over the past years. This is quite good.
EPS 1Y (TTM)3.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.49%
Revenue 1Y (TTM)-82.74%
Revenue growth 3Y-67.26%
Revenue growth 5Y15.66%
Sales Q2Q%-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AIMD Yearly Revenue VS EstimatesAIMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AIMD. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AIMD Price Earnings VS Forward Price EarningsAIMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AIMD Per share dataAIMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

AIMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AINOS INC

NASDAQ:AIMD (5/21/2025, 8:00:00 PM)

After market: 0.488 +0 (+0.74%)

0.4844

-0.04 (-8.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)08-04 2025-08-04
Inst Owners0.56%
Inst Owner Change49.07%
Ins Owners11.16%
Ins Owner Change16.87%
Market Cap7.47M
AnalystsN/A
Price TargetN/A
Short Float %15.54%
Short Ratio1.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 361.08
P/FCF N/A
P/OCF N/A
P/B 0.48
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.72
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS0
BVpS1.01
TBVpS-0.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.57%
ROE -95.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.19%
ROA(5y)-139.96%
ROE(3y)-64.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.44%
Cap/Sales 102.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.1
Quick Ratio 1.06
Altman-Z -3.76
F-Score2
WACC7.12%
ROIC/WACCN/A
Cap/Depr(3y)5.13%
Cap/Depr(5y)24.45%
Cap/Sales(3y)65.65%
Cap/Sales(5y)54.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.49%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-82.74%
Revenue growth 3Y-67.26%
Revenue growth 5Y15.66%
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-21.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.72%
OCF growth 3YN/A
OCF growth 5YN/A